alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 66, Number 115 (Thursday, June 14, 2001)]
[Notices]
[Pages 32362-32363]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-14965]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel In Vivo Cellular and Molecular Imaging Centers.
    Date: July 18-19, 2001.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriot, 5151 Pooks Hill Road, Bethesda, MD 
20814.
    Contact Person: Timothy C. Meeker, MD., Scientific Review 
Administrator, Special Referral and Resources Branch, Division of 
Extramural Activities, National Cancer Institute, 6116 Executive 
Boulevard, room 8088, Rockville, MD 20852, 301/594-1279.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention

[[Page 32363]]

Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, 
Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, 
Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, 
Cancer Control, National Institutes of Health, HHS)


    Dated: June 7, 2001.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-14965 Filed 6-13-01; 8:45 am]
BILLING CODE 4140-01-M
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE>             5
<MULTIPLIER>          1

<S>                   <C>
<PERIOD-TYPE>         12-MOS
<FISCAL-YEAR-END>     DEC-31-1998
<PERIOD-END>          DEC-31-1998
<CASH>                661
<SECURITIES>          0
<RECEIVALBES>         0
<ALLOWANCES>          0
<INVENTORY>           0
<CURRENT-ASSETS>      661
<PP&E>                0
<DEPRECIATION>        0
<TOTAL-ASSETS>        661
<CURRENT-LIABILITIES>        154,317
<BONDS>                      0
<PREFERRED-MANDATORY>        0
<PREFERRED>                  0
<COMMON>                     85,045
<OTHER-SE>                   0
<TOTAL-LIABILTY-AND-EQUITY>  239,362
<SALES>                      0
<TOTAL-REVENUES>             0
<CGS>                        0
<TOTAL-COSTS>                0
<OTHER-EXPENSES>             42,824
<LOSS-PROVISION>             0
<INTEREST-EXPENSE>           0
<INCOME-PRETAX>              0
<INCOME-TAX>                 0
<INCOME-CONTINUING>          0
<DISCONTINUED>               0
<EXTRAORDINARY>              0
<CHANGES>                    0
<NET-INCOME>                 (42,824)
<EPS-BASIC>                (0.00)
<EPS-DILUTED>                (0.00)


</TABLE>
Page 1 

Commodity Futures Trading Commission 

CEA CASES 

NAME: MOUSTAPHA AHMAD TABBARA 

DOCKET NUMBER: 132 

DOCUMENT TYPE: ISSUANCE OF COMPLAINT 

UNITED STATES DEPARTMENT OF AGRICULTURE 

Commodity Exchange Authority 

Washington, D.C. 20250 

ISSUANCE OF COMPLAINT -- CEA DOCKET NO. 132 

(Administrative Hearing under the Commodity Exchange Act) 

A complaint and notice of hearing has been signed by the Assistant Secretary 

of Agriculture, charging violation of the Commodity Exchange Act by: 

Moustapha Ahmad Tabbara 

(Sao Paulo, Brazil and Beirut, Lebanon) 

The complaint charges that on 29 business days during the period September 

14, 1964, through July 29, 1965, the respondent failed or refused to submit 

reports to the Commodity Exchange Authority concerning trades and positions in 

wheat futures owned or controlled by him. The complaint also charges that on 33 

business days during this period the respondent filed false reports with respect 

to trading and positions in wheat futures. 

The issuance of a complaint under the Commodity Exchange Act does not 

constitute proof of violation of the law. Such violation is established only 

when the Judicial Officer of the Department has made a determination that the 

evidence substantiates allegations in the complaint. Complaints are filed in 

the Office of the Hearing Clerk of the Department of Agriculture and are a 

matter of public record. Pending disposition by the Judicial Officer, it is the 

policy of the Commodity Exchange Authority not to comment or elaborate on 

charges contained in complaints or to discuss evidence on which they are based. 

A public hearing on the complaint is scheduled to be held before a referee at 

10:00 a.m., local time, February 1, 1966, in Washington, D. C. 

LOAD-DATE: June 12, 2008 
Page 2
EXHIBIT 99.1



                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         In connection with the quarterly report of SiriCOMM, Inc. (the
"Company") on Form 10-QSB for the period ending March 31, 2003 as filed with the
Securities and Exchange Commission on May 20, 2003 (the "Report"), I, Henry P.
Hoffman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002,
that:

         (1)      The Report fully complies with the requirements of section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)      The information contained in the Report fairly presents, in
                  all material respects, the financial condition and result of
                  operations of the Company.



/s/ Henry P. Hoffman
---------------------------
Henry P. Hoffman
Chief Executive Officer
May 19, 2003
---

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly
Report of Swav Enterprises Ltd., a Nevada corporation (the Registrant), on
Form 10-Q for the period ended December 31, 2009 as filed with the Securities
and Exchange Commission on the date hereof (the Report), I, Vanleo Y. W. Fung,
the Principal Financial Officer and Principal Accounting Officer of the
Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended; and

(2) the information contained in
the Report fairly presents, in all material respects, the financial condition
and results of operations of the Registrant.

| | /s/ Vanleo Y.W. Fung                                 
| | -----------------------------------------------------
| | Vanleo Y.W. Fung                                     
| | Chief Financial Officer, Secretary and
      Director
| | (Principal Financial Officer and
      Principal     
| | Accounting Officer)                                  
| | Date: February 22, 2010                              

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### International Trade Administration

                    Pursuant to Section 6(c) of the Educational, Scientific and Cultural                           ( print page 32601)                        Materials Importation Act of 1966 (Pub. L. 89-651; 80 Stat. 897; 15 CFR part 301), we invite comments on the question of whether an instrument of equivalent scientific value, for the purposes for which the instrument shown below is intended to be used, is being manufactured in the United States.                

Comments must comply with 15 CFR 301.5(a)(3) and (4) of the regulations and be filed within 20 days with the Statutory Import Programs Staff, U.S. Department of Commerce, Washington, DC 20230. Applications may be examined between 8:30 A.M. and 5:00 P.M. in Room 4211, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC.

*Docket Number:*                     01-012.                     *Applicant:*                     Rutgers University, Department of Physics and Astronomy, 136 Frelinghuysen Road, Piscataway, NJ 08854-8019.                     *Instrument:*                     Floating-Zone Optical Furnace, Model FZ-T-10000-H-VI-VP.                     *Manufacturer:*                     Crystal Systems, Inc., Japan.                     *Intended Use:*                     The instrument is intended to be used to grow oxide single crystals such as (La,Ca)MnOq                    3                    , SrTiO                    3                    , CuGeO                    3                    , and La                    2                    CuO                    4                     to investigate new magnetic and electronic ground states using the floating-zone crystal growth technique.                     *Application accepted by Commissioner of Customs:*                     May 9, 2001.                

Gerald A. Zerdy,

Program Manager, Statutory Import Programs Staff.

[FR Doc. 01-15074 Filed 6-14-01; 8:45 am]

BILLING CODE 3510-DS-P
# FCM Data March 2010
| 1.     | Such      Quarterly Report of Form 10-Q for the period ending September      30, 2008, fully complies with the requirements of Section 13(a) or 15(d)      of the Securities Exchange Act of 1934; and                                                          |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |
| 2.     | The      information contained in such Quarterly Report on Form 10-Q for      the period ended September 30, 2008, fairly represents in all      material respects, the financial condition and results of operations of      Kraig Biocraft Laboratories, Inc. |

| Date:       November 13, 2008                                                      |
|-----------------------------------------------------------------------------------------|
|                                                                                    |
| Kraig      Biocraft Laboratories, Inc.                                                  |
|                                                                                    |
| By: /s/      Kim      Thompson                                                          |
| Kim      ThompsonChief      Executive OfficerChief      Financial and AccountingOfficer |
H. Res. 1415 

In the House of Representatives, U. S., 

May 28, 2010. 

Resolved, That the following named Members be, and 

they are hereby, elected to the following standing committees 

of the House of Representatives: 

COMMITTEE ON ARMED SERVICES: Mr. Djou. 

COMMITTEE ON THE BUDGET: Mr. Djou. 

COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM: Mr. Shuster. 

Attest: 

Clerk.
Exhibit 32  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEYACT OF 2002  In connection with the Annual Report on Form 10-K of Marvel Entertainment, Inc.
(the Company)  for the fiscal year ended December 31,  2005 as filed with the
Securities and Exchange Commission on the date hereof (the Report), we, Isaac   Perlmutter and Kenneth P. West, Chief Executive Officer and Chief Financial
Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. ss. 1350,
as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:  (1) The Report fully complies with the requirements of section 13(a) or 15(d)    of the Securities Exchange Act of 1934; and  (2)  The information contained in the Report fairly presents, in all material     respects, the financial condition and result of operations of the Company.   /s/ Isaac Perlmutter  ----------------------------------------- Isaac Perlmutter Chief Executive Officer March 15, 2006  /s/ Kenneth P. West  ------------------------------ Kenneth P. West Chief Financial Officer March 15, 2006  A signed original of this written statement required by Section 906 has been provided to Marvel Entertainment, Inc. and will be retained by Marvel Entertainment, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
EXHIBIT 32




CERTIFICATION PURSUANT TO
 18 U.S.C. 1350,
 CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
 PURSUANT TO 18 U.S.C. SECTION 1350
  In connection with this Quarterly Report of AMERELITE SOLUTIONS, INC. (the “Company”) on Form 10-Q for the period ending June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert L. Knapp, Chief Executive Officer and Chief Financial Officer f the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
 
 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
   Date: December 15, 2010
By:
/s/  Robert L. KnappRobert L. KnappPrincipal Executive OfficerPrincipal Financial Officer
# FCM Data December 2016
Exhibit
32
 CERTIFICATION
OF CHIEF EXECUTIVE OFFICER
 AND CHIEF
FINANCIAL OFFICER PURSUANT TO
 18 U.S.C.
SECTION 1350,
 AS
ADOPTED PURSUANT TO
 SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002*
 
 I, Gary
S. Kledzik, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of
Miravant Medical Technologies on Form 10-K for the fiscal year ended December
31, 2004 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in such Annual
Report on Form 10-K fairly presents in all material respects the financial
condition and results of operations of Miravant Medical Technologies.
 
 
 By:  /s/
Gary S. Kledzik
 Name:
Gary S. Kledzik
 Title:
Chief Executive Officer
 
 
 I, John
M. Philpott, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of
Miravant Medical Technologies on Form 10-K for the fiscal year ended December
31, 2004 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in such Annual
Report on Form 10-K fairly presents in all material respects the financial
condition and results of operations of Miravant Medical Technologies.
 
 
 By:  /s/
John M. Philpott
 Name:
John M. Philpott
 Title:
Chief Financial Officer
 
 * A
signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
required by Section 906, has been provided to Miravant Medical Technologies and
will be retained by the company and furnished to the Securities and Exchange
Commission or its staff upon request.
IN THE SUPREME COURT OF PENNSYLVANIA WESTERN DISTRICT COMMONWEALTH OF PENNSYLVANIA, Respondent

v. PAUL FAVERS, Petitioner : : : : : : : : : : : No. 113 WAL 2015 Petition for Allowance of Appeal from the Order of the Superior Court

ORDER PER CURIAM AND NOW , this 4th day of August, 2015, the Petition for Allowance of Appeal is DENIED
.
EXHIBIT 32.2

CERTIFICATION
PURSUANT TO

18 U.S.C.
SECTION 1350,

AS ADOPTED
PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection
with the Annual Report of PowerVerde, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2012 as
filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John L. Hofmann, Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act
of 2002, that:

| | (1) | The
                                         Report fully complies with the requirements of section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | (2) | The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and results of operations of the Company.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|/s/
    John L. Hofmann     | 
|--------------------------- | 
|John L. Hofmann             | 
|Chief Financial
    Officer | 
|February 14, 2014           | 

8
Exhibit






Exhibit 10.2


ALPHA AND OMEGA SEMICONDUCTOR LIMITED
CALENDAR YEAR 2016 EXECUTIVE INCENTIVE PLAN


The following is a summary of the operation of the Executive Incentive Plan (the “Plan”) established by Alpha and Omega Semiconductor Limited (the “Company”) for the calendar year ending December 31, 2016.


Participants


Executive officers and Vice Presidents.


Performance Bonus


Participants are eligible to receive a bonus based on the level of attainment of pre-specified corporate performance goals. The Company’s compensation committee establishes the performance goals to be attained.


Performance Goals


The corporate performance goals for calendar year 2016 are revenue and non-GAAP operating income (after bonus payout). The amount of bonus earned is based on the level of attainment of a range of revenue and non-GAAP operating income for the year. A specified minimum amount of each of the revenue and non-GAAP operating income goals must be achieved before payment of an award under the Plan.The actual aggregate amount of the award earned by an executive officer for the calendar year will range from $0 to the maximum amount established for that officer (as set forth below) depending on the level of attainment of the performance goals. As used herein, the term “non-GAAP operating income” means the Company’s operating income as determined in accordance with U.S. GAAP but excluding (i) share-based compensation expenses recorded under FASB ASC Topic 718; (ii) impairment of long-lived assets; (iii) non-recurring inventory write-down; (iv) acquisition cost; and (v) any other adjustment made to arrive at the Company’s non-GAAP operating income as presented in the Company filings with the Securities Exchange Commission, including any Item 2.02 disclosures on Form 8-K relating to the Company’s quarterly financial information. 


Payment of Awards: Cash and RSU Pool


The amount of the bonus award will be paid in a combination of cash and restricted share units (“RSU”) covering shares of Company common shares (with the number of shares based on the closing price of the common shares on the last trading date of the year). The specific allocation between cash and RSUs in the bonus award will vary depending on the level of attainment of the non-GAAP operating income and annual revenue goals, provided that the number of RSUs to be granted may not exceed certain dilution cap. RSU award will vest in four equal annual installments subject to the executive officer’s continued service through each vesting date.  


Target Bonus Awards


The Company’s compensation committee establishes the bonuses payable based on the level of attainment of the corporate performance goals. The target bonuses for each executive officer for calendar year 2016, as a percentage of base salary, are as follows: 




	
					
	 

	 
	 
	 
	 
	 

	Name
	Title
	Minimum Bonus
	Target Bonus
	Maximum Bonus

	Mike F. Chang
	Chief Executive Officer
	20%
	100%
	220%

	Yifan Liang
	Chief Financial Officer and Corporate Secretary
	12%
	60%
	132%

	Yueh-Se Ho
	Chief Operating Officer
	12%
	60%
	132%

	Daniel Kuang Ming Chang
	Senior Vice President of Marketing
	10%
	50%
	110%